JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $135

Benzinga Newsdesk www.benzinga.com Positive 75.9%

Neg 0% Neu 0% Pos 75.9%

JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $125 to $135.